Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OraBan is a mucoadhesive protective paste developed by Sultan Healthcare for the symptomatic relief of oral mucosal irritations, including aphthous ulcers (canker sores), denture sores, and traumatic lesions. The product is formulated with a combination of gelatin, pectin, and sodium carboxymethylcellulose in a mineral oil and polyethylene base, which allows it to adhere effectively to moist oral tissues. Its primary mechanism of action is the creation of a physical, mechanical barrier that shields sensitive nerve endings from chemical and mechanical triggers such as food, drink, and tongue movement. By providing this protective 'bandage,' OraBan reduces pain and facilitates the natural healing of the oral mucosa without the need for active pharmacological agents like steroids or local anesthetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OraBan.